PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 04:10:48 2024-06-14 am EDT | ||
| 8.34 EUR | +0.97% |
|
| Current month | -7.40% | ||
| 1 month | -8.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 8.34 | +0.97% |
| 24-06-13 | 8.26 | -2.48% |
| 24-06-12 | 8.47 | -4.19% |
| 24-06-11 | 8.84 | +0.91% |
| 24-06-10 | 8.76 | +0.11% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 04:10 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU8LNL |
| ISIN | DE000VU8LNL8 |
| Date issued | 2023-06-14 |
| Strike | 319.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.22 € |
|---|---|
| Lowest since issue | 1.45 € |
| Spread | 0.17 € |
| Spread % | 1.99% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
233.8
USD
Average target price
284.6
USD
Spread / Average Target
+21.73%
- Stock Market
- Certificates
- Certificat
